Contact Us
Drug Search Results
More Filters [+]

IBI-379

Alternative Names: IBI-379, IBI379, IBI 379
Latest Update: None
Latest Update Note: None

Product Description

IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma. A bispecific T cell engager, IBI379, that targets BCMA and CD3, and investigated its antitumor efficacy against MM. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/35381307/)

Mechanisms of Action: BCMA Inhibitor,CD3 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Innovent Biologics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IBI-379

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions